Research
Energy balance
The net increased spending due to expanded Medicare coverage for GLP-1RAs is projected to be $47.7 billion over 10 years.
Practitioners should be aware of the substantial net spending implications of GLP-1RA coverage.
StrongSupportsmedium confidence
resulting in net increased spending of $47.7 billion.
Why this rating
Based on the economic evaluation design stated in the abstract.
Source
Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity
Jennifer H. Hwang et al. · JAMA Health Forum · 2025
DOI 10.1001/jamahealthforum.2025.0905
other · n=30000000Cited 27×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Expanded Medicare coverage for GLP-1 receptor agonists (GLP-1RAs) for obesity treatment is projected to increase total Medicare drug costs by $65.9 billion over 10 years.Strong
- The estimated health care cost offsets from clinical benefits of GLP-1RAs are projected to be $18.2 billion over 10 years.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →